natgillin/translations-raw huggingface dataset:
There are insufficient data on the incidence of delayed hypersensitivity reactions after Remicade-free intervals of more than 1 year but limited data from clinical studies suggest an increased risk for delayed hypersensitivity with increasing Remicade-free interval (see section 4.4). 
Podatki o incidenci poznih preobčutljivostnih reakcij po premoru brez zdravila Remicade, daljšem od enega leta, so nezadostni, vendar omejeni podatki iz kliničnih preskušanj kažejo povečano tveganje za pozno preobčutljivost pri povečevanju premora brez zdravila Remicade (glejte poglavje 4.4).
EXPRESS Placebo → Infliximab 5 mg/kg (at week 24) 
EXPRESS placebo → infliximab 5 mg/kg (24 teden)
In most fistulising Crohn's disease patients, infliximab was detected in serum for 12 weeks (range 4-28 weeks) after administration of the regimen. 
Pri večini bolnikov s Crohnovo boleznijo s fistulami so infliksimab ugotavljali v serumu še 12 tednov (razpon: od 4 do 28 tednov) po infuziji.
The combination of Remicade with other biological therapeutics used to treat the same conditions as Remicade, including anakinra and abatacept, is not recommended (see section 4.4). 
Kombiniranje zdravila Remicade z drugimi biološkimi zdravili za zdravljenje enakih bolezni kot z zdravilom Remicade, vključno z anakinro in abataceptom, ni priporočljivo (glejte poglavje 4.4).
PGA of cleared (0) or minimal (1) 
PGA brez plakov (0) ali minimalni (1)
Limited experience from re-treatment with one single Remicade dose in psoriasis after an interval of 20 weeks suggests reduced efficacy and a higher incidence of mild to moderate infusion reactions when compared to the initial induction regimen (see section 5.1). 
Omejene izkušnje s ponovnim zdravljenjem z enim samim odmerkom zdravila Remicade pri psoriazi po časovnem presledku 20 tednov kažejo zmanjšano učinkovitost in večjo incidenco blagih do zmernih z infuzijo povezanih reakcij v primerjavi s prvotnim uvodnim režimom zdravljenja (glejte poglavje 5.1).
> 40 weeks 
> 40 tednov
(DMARDs), including methotrexate, has been inadequate. 
(DMARD - disease modifying antirheumatic drugs), ki vplivajo na imunsko odzivnost, vključno z metotreksatom, ni zadosten.
Elevations of aminotransferases were observed (ALT more common than AST) in a greater proportion of patients receiving Remicade than in controls, both when Remicade was given as monotherapy and when it was used in combination with other immunosuppressive agents. 
Zvišanje aminotransferaz (ALT pogosteje kot AST) so opažali pri večjem deležu bolnikov, ki so prejemali zdravilo Remicade, kot v kontrolni skupini, in sicer tako med dajanjem zdravila Remicade v monoterapiji kot pri njegovi uporabi v kombinaciji z drugimi imunosupresivnimi sredstvi.
> 54 weeks 
> 54 tednov
It is not known whether this finding was due to effects on the males and/or the females. 
Ni znano, ali je to posledica učinka zdravila na samce, na samice ali na oba spola.
All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor). 
Vsem bolnikom svetujte, naj takoj poiščejo zdravniško pomoč, če se jim pojavijo znaki in simptomi, ki kažejo na krvno diskrazijo (npr. trdovratna zvišana telesna temperatura, podplutbe, krvavitve in bledica).
Available data suggest an increased risk for delayed hypersensitivity with increasing Remicade-free interval. 
Podatki, ki so na voljo, kažejo povečano tveganje za pozno preobčutljivost pri povečevanju premora brez prejemanja zdravila Remicade.
• Tell your doctor before you are given Remicade if you have or have ever had lymphoma (a type of blood cancer) or any other cancer. 
• Preden prejmete zdravilo Remicade, povejte zdravniku, če imate ali ste imeli kdaj v preteklosti limfom (vrsta krvnega raka) oziroma katero koli drugo vrsto raka.
Histological evaluation of colonic biopsies, obtained before and 4 weeks after administration of infliximab, revealed a substantial reduction in detectable TNF. 
Histološka preiskava biopsijskih vzorcev kolona, odvzetih pred uporabo infliksimaba in 4 tedne po njej, je pokazala znatno zmanjšanje merljivega TNF.
• If you received Remicade during your pregnancy, your baby may have a higher risk for getting an infection. 
• Če ste v času nosečnosti prejemali zdravilo Remicade, ima vaš dojenček lahko povečano tveganje za okužbe.
In psoriatic arthritis patients who received 5 mg/kg with and without methotrexate, antibodies occurred overall in 15% of patients (antibodies occurred in 4% of patients receiving methotrexate and in 26% of patients not receiving methotrexate at baseline). 
Pri bolnikih s psoriatičnim artritisom, ki so prejemali odmerek 5 mg/kg z ali brez metotreksata, so našli protitelesa pri skupaj 15 % bolnikov (protitelesa so se pojavila pri 4 % bolnikov, ki so prejemali metotreksat in pri 26 % bolnikov, ki niso prejemali metotreksata na začetku študije).
In case maintenance therapy is interrupted, and there is a need to restart treatment, use of a re-induction regimen is not recommended (see section 4.8). 
V primeru prekinitve vzdrževalnega zdravljenja in potrebe po ponovni uvedbi zdravljenja ni priporočljiva ponovna uporaba uvodne sheme (glejte poglavje 4.8).
Before starting treatment with Remicade, all patients must be evaluated for both active and inactive (‘latent') tuberculosis. 
Pred začetkom zdravljenja z zdravilom Remicade, morate vse bolnike pregledati in preiskati, da ugotovite morebitno aktivno ali neaktivno (latentno) tuberkulozo.
During clinical studies of Remicade across all approved indications the incidence of lymphoma in Remicade-treated patients was higher than expected in the general population, but the occurrence of lymphoma was rare. 
Med kliničnimi preskušanji zdravila Remicade za vse odobrene indikacije je bila pri bolnikih, zdravljenih z zdravilom Remicade, incidenca limfoma višja od pričakovane za splošno populacijo, vendar se je limfom dejansko pojavljal redko.
In psoriasis patients treated with infliximab as a maintenance regimen in the absence of concomitant immunomodulators, approximately 28% developed antibodies to infliximab (see section 4.4: “Infusion reactions and hypersensitivity”). 
Pri bolnikih, ki so jim psoriazo vzdrževalno zdravili z infliksimabom brez spremljajočega imunomodulatorja, so se pri približno 28 % razvila protitelesa proti infliksimabu (glejte poglavje 4.4: ''Z infuzijo povezane reakcije in preobčutljivost'').
Patients who have inflammatory diseases already take medicines to treat their problem. 
Bolniki z vnetnimi boleznimi že prejemajo zdravila za zdravljenje le teh.
• or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated 
• ali samostojno pri bolnikih, ki ne prenašajo metotreksata ali pri katerih je metotreksat kontraindiciran.
In clinical studies, infections have been reported in a higher proportion of paediatric patients compared to adult patients (see section 4.8). 
V kliničnih študijah so o okužbah poročali pogosteje pri pediatričnih bolnikih kot pri odraslih bolnikih (glejte poglavje 4.8).
Remicade works by selectively attaching to TNF alpha and blocking its action. 
Zdravilo Remicade deluje tako, da se selektivno veže na TNF-alfa in zavira njegovo delovanje.
Table 5 Effects on response and remission rate, data from ACCENT I (week-2 responders) ACCENT I (week-2 responders) % of Patients 
Preglednica 5 Učinki na stopnjo odziva in ponovitev bolezni pri bolnikih; podatki iz študije ACCENT I (bolniki z odzivom v 2. tednu) ACCENT I (bolniki z odzivom v 2. tednu) % bolnikov
Indication Number of patients 
Število bolnikov
optic neuritis and Guillain-Barré syndrome 
vnetje vidnega živca in Guillain-Barréjev sindrom
Patients may be pre-treated with e.g., an antihistamine, hydrocortisone and/or paracetamol and infusion rate may be slowed in order to decrease the risk of infusion-related reactions especially if infusion-related reactions have occurred previously (see section 4.4). 
Za zmanjšanje tveganja za pojav z infuzijo povezanih reakcij lahko bolnikom že prej date npr. antihistaminik, hidrokortizon in/ali paracetamol in upočasnite hitrost infundiranja, še posebej če so se z infuzijo povezane reakcije pojavile že kdaj prej (glejte poglavje 4.4).
There were no serious infusion reactions, and 2 subjects in REACH had non-serious anaphylactic reactions. 
Ni bilo nobene resne z infuzijo povezane reakcije, dva preiskovanca v preskušanju REACH pa sta imela anafilaktično reakcijo, ki ni bila resna.
Studies have not been performed in patients with liver or renal disease. 
Tudi študij pri bolnikih z jetrno ali ledvično boleznijo ni bilo.
In clinical studies, delayed hypersensitivity reactions have been reported. 
V kliničnih preskušanjih so poročali o poznih preobčutljivostnih reakcijah.
Chemical and physical in use stability of the diluted solution has been demonstrated for up to 28 days at 2 °C to 8 °C and for an additional 24 hours at 25 °C after removal from refrigeration. 
Dokazano je bilo, da je razredčena raztopina zdravila Remicade kemično in fizikalno stabilna do 28 dni pri temperaturi 2 °C do 8 °C ter dodatnih 24 ur pri temperaturi 25 °C, po tem ko se vzame iz hladilnika.
Type 1 glass vial with rubber stopper and aluminium crimp protected by a plastic cap. 
Viala (steklo tipa 1) z gumijastim zamaškom in aluminijasto zaporko, zaščiteno s plastično ploščico.
Calculate the total volume of reconstituted Remicade solution required. 
Izračunajte celoten volumen potrebne rekonstituirane raztopine zdravila Remicade.
Elevations of ALT ≥ 5 x Upper Limit of Normal (ULN) have been observed (see Table 2). 
Opazili so zvišanje vrednosti ALT na ≥ 5-kratnik zgornje meje normalnih vrednosti (glejte preglednico 2).
At baseline 53% of patients were receiving immunomodulator therapy (6-MP, AZA and/or MTX) and 62% of patients were receiving corticosteroids. 
Na začetku študije je 53 % bolnikov prejemalo imunomodulatorje (6-MP, AZA in/ali MTX), 62 % bolnikov pa je prejemalo kortikosteroide.
Psoriatic arthritis, ankylosing spondylitis (Bechterew's disease), psoriasis, ulcerative colitis and Crohn's disease 
Psoriatični artritis, ankilozirajoči spondilitis (Bechterew sindrom), psoriaza, ulcerozni kolitis in Crohnova bolezen
Remicade is produced in packs of 1, 2, 3, 4 or 5 vials. 
Zdravilo Remicade je pakirano po 1, 2, 3, 4 ali 5 vial.
Corticosteroid taper was permitted after week 8. 
Zmanjševanje odmerka kortikosteroidov je bilo dovoljeno po 8. tednu.
• Fast heart beat (tachycardia) or palpitations 
• hitro bitje srca (tahikardija) ali razbijanje (palpitacije)
Particular attention regarding the risk for infection should be paid when treating the elderly (see section 4.8). 
Pri zdravljenju starejših je torej treba posvetiti posebno pozornost tveganju za nastanek okužbe (glejte poglavje 4.8).
Corticosteroids do not appear to affect the pharmacokinetics of infliximab to a clinically relevant extent. 
Ni videti, da bi imeli kortikosteroidi klinično pomemben vpliv na farmakokinetiko infliksimaba.
Patients were followed up to 26 weeks. 
Spremljali so jih do 26 tednov.
Table 10 Summary of PASI response, PGA response and percent of patients with all nails cleared at weeks 10, 24 and 50. 
Preglednica 10 Povzetek odzivov PASI,vrednosti PGA in delež bolnikov z nohti brez psoriatičnih sprememb v 10, 24 in 50 tednu.
At week 2, all patients were assessed for clinical response and randomised to one of 3 treatment groups; a placebo maintenance group, 5 mg/kg maintenance group and 10 mg/kg maintenance group. 
V drugem tednu zdravljenja so pri vseh bolnikih ocenili klinični odziv in jih naključno razvrstili v eno od 3 terapevtskih skupin: skupino za vzdrževalno zdravljenje s placebom, skupino za vzdrževalno zdravljenje z odmerkom 5 mg/kg in skupino za vzdrževalno zdravljenje z odmerkom 10 mg/kg.
The educational programme consists of a patient reminder card to be held by the patient. 
Izobraževalni program obsega opozorilno kartico za bolnika, ki jo ima bolnik pri sebi.
Concurrent use of stable doses of conventional therapies was permitted, and 92% of patients continued to receive these therapies. 
Sočasno jemanje stalnih odmerkov konvencionalnih zdravil je bilo dovoljeno in 92 % bolnikov je med študijo še naprej prejemalo to terapijo.
Patients who were randomised to the placebo maintenance group and then later crossed over to infliximab are included in the infliximab group in the ALT analysis. 
Bolniki, ki so jih naključno razporedili v skupino za vzdrževalno zdravljenje s placebom in so potem prešli v skupino za zdravljenje z infliksimabom, so bili pri analizi ALT vključeni v infliksimabovo skupino.
Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed taking into account both the risk for severe fungal infection and the risks of antifungal therapy. 
Med izvajanjem diagnostičnih preiskav je treba razmisliti o ustreznem empiričnem protiglivičnem zdravljenju, upoštevajoč tako tveganje za hudo glivično okužbo kot tudi tveganja samega protiglivičnega zdravljenja.
There are no known side effects of having too much of Remicade. 
Ni poznanih neželenih učinkov zaradi prejetja prevelikega odmerka zdravila Remicade.
• Inflamed liver caused by a problem with the immune system (autoimmune hepatitis) 
• vneta jetra zaradi težav z imunskim sistemom (avtoimunski hepatitis)
The reduction in incidence of colectomy was also examined in another randomised, double-blind study (C0168Y06) in hospitalised patients (n = 45) with moderately to severely active ulcerative colitis who failed to respond to intravenous corticosteroids and who were therefore at higher risk for colectomy. 
Zmanjšanje incidence kolektomij so proučevali še v eni randomizirani, dvojno slepi študiji (C0168Y06) pri hospitaliziranih bolnikih (n = 45) z zmerno do močno aktivnim ulceroznim kolitisom, ki se niso odzvali na zdravljenje z intravenskimi kortikosteroidi in so imeli zato večje tveganje, da bo pri njih potrebna kolektomija.
Immunogenicity Antibodies to infliximab were detected in 4 (7.7%) patients through week 54. 
Imunogenost Protitelesa proti infliksimabu so v obdobju do konca 54. tedna ugotovili pri 4 (7,7 %) bolnikih.
19 weeks 
19 tednov
Appropriate screening tests (e.g. tuberculin skin test, chest X-ray, and/or Interferon Gamma Release Assay), should be performed in all patients (local recommendations may apply). 
Pri vseh bolnikih je treba opraviti ustrezne presejalne teste (npr. tuberkulinski kožni test, rentgensko slikanje prsnega koša in/ali test sproščanja interferona gama) (v skladu z lokalnimi priporočili).
Patients should be advised to seek immediate medical advice if they experience any delayed adverse reaction (see section 4.8). 
Bolnikom naročite, naj nemudoma poiščejo zdravniško pomoč, če opazijo katerega od poznih neželenih učinkov (glejte poglavje 4.8).
Administer the infusion solution over a period of not less than the infusion time recommended (see section 4.2). 
Infuzijsko raztopino infundirajte bolniku v času, ki naj ne bo krajši od priporočenega trajanja infuzije (glejte poglavje 4.2).
In both studies, physical function and quality of life as measured by the BASFI and the physical component score of the SF-36 were also improved significantly. 
V obeh študijah sta se bistveno izboljšala telesno stanje bolnikov in kakovost njihovega življenja merjeno po lestvici BASFI, pa tudi telesna komponenta ocene po SF-36 je bila bistveno izboljšana.
All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before therapy and throughout their disease course. 
Pri vseh bolnikih z ulceroznim kolitisom, pri katerih obstaja povečano tveganje za displazijo ali karcinom kolona (na primer pri bolnikih z dolgotrajnim ulceroznim kolitisom ali primarnim sklerozantnim holangitisom) ter pri tistih, ki imajo displazijo ali karcinom kolona v pretekli anamnezi, morate redno opravljati presejalne teste za displazijo, tako pred zdravljenjem kot med samo boleznijo.
• In case you have received Remicade while you were pregnant, it is important that you inform your baby's doctor about it before your baby receives any vaccine. 
• Če ste med nosečnostjo prejeli zdravilo Remicade, je pomembno, da o tem obvestite zdravnika vašega dojenčka, preden dojenček prejme katero koli cepivo.
Almost all patients had received treatment with AZA or 6-MP concomitantly with or immediately prior to a TNF-blocker. 
Skoraj vsi bolniki so bili zdravljeni z AZA ali 6-MP, bodisi sočasno z zaviralcem TNF ali neposredno pred uporabo zaviralca TNF.
• It is very important that you tell your doctor if you have ever had TB, or if you have been in close contact with someone who has had TB. 
• Zelo pomembno je, da zdravniku poveste, če ste kdaj imeli tuberkulozo ali če ste bili v tesnem stiku s tuberkuloznim bolnikom.
Efficacy and safety were assessed in two multicenter, double-blind, placebo-controlled studies in patients with active psoriatic arthritis. 
Učinkovitost in varnost zdravila so ocenjevali v dveh multicentričnih, dvojno slepih in s placebom kontroliranih študijah pri bolnikih z aktivnim psoriatičnim artritisom.
• Do not use this medicine if it is discoloured or if there are particles present. 
• Ne uporabljajte tega zdravila, če opazite, da je raztopina spremenila barvo ali če vsebuje delce.
Concomitant stable doses of oral aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted. 
Dovoljeni so bili sočasni stalni odmerki peroralnih aminosalicilatov, kortikosteroidov in/ali imunomodulatorjev.
• Convulsions, nerve problems 
• epileptični krči, težave z živčevjem
Median follow-up is based on patients treated. 
Mediana dolžine spremljanja bolnikov je bila določena samo z upoštevanjem zdravljenih bolnikov.
If jaundice and/or ALT elevations ≥ 5 times the upper limit of normal develop(s), Remicade should be discontinued, and a thorough investigation of the abnormality should be undertaken. 
Če se pojavi zlatenica in/ali zvišanje vrednosti ALT ≥ 5-kratno zgornjo mejo normale, prenehajte z uporabo zdravila Remicade in temeljito raziščite vzroke za nenormalne izvide.
While the numbers of patients in each subgroup are too small to make any definitive conclusions about the effect of age on safety events, there were higher proportions of patients with serious adverse events and discontinuation due to adverse events in the younger age group than in the older age group. 
Število bolnikov v vsaki podskupini je sicer premajhno, da bi dopuščalo dokončne sklepe o vplivu starosti na varnost zdravljenja, vendar pa sta bila deleža bolnikov z resnimi neželenimi učinki in s prekinitvijo zdravljenja zaradi neželenih učinkov v mlajši starostni skupini večja kot v starejši.
Corticosteroid tapering was permitted after week 6. 
Zmanjševanje odmerka kortikosteroida je bilo dovoljeno po 6. tednu.
• Possible signs of cancer including but not limited to swelling of lymph nodes, weight loss, fever, unusual skin nodules, changes in moles or skin colouring, or unusual vaginal bleeding. 
• možni znaki raka, vključno z, vendar ne omejeno na otekanje bezgavk, izgubo telesne mase, zvišano telesno temperaturo, nenavadnimi kožnimi vozliči, spremembami znamenj ali barve kože, ali nenavadne vaginalne krvavitve.
If you forget or miss an appointment to receive Remicade, make another appointment as soon as possible. 
Če ste pozabili ali izpustili odmerek zdravila Remicade Če ste pozabili ali izpustili dogovorjen termin, da bi prejeli zdravilo Remicade, se čim prej dogovorite za naslednjega.
In the 3 mg/kg Remicade group, 4 out of 60 patients had a serious infusion reaction and 3 patients reported a possible anaphylactic reaction (2 of which were among the serious infusion reactions). 
V skupini, ki je zdravilo Remicade prejemala v odmerku 3 mg/kg, so imeli 4 od 60-tih bolnikov resno z infuzijo povezano reakcijo, pri 3 pa so poročali o možni anafilaktični reakciji (od tega sta 2 sodili med resne z infuzijo povezane reakcije).
In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated (see section 5.1). 
V teh populacijah bolnikov so pokazali zmanjšanje hitrosti napredovanja okvare sklepov, ki so jo ugotavljali z rentgenskim slikanjem (glejte poglavje 5.1).
Therefore, the combination of Remicade and anakinra is not recommended. 
Kombiniranje zdravila Remicade in anakinre torej ni priporočljivo.
• Patients with COPD and patients who are heavy smokers may have a higher risk of developing cancer with Remicade treatment. 
• Bolniki s KOPB in tisti, ki veliko kadijo, imajo lahko povečano tveganje za nastanek raka pri zdravljenju z zdravilom Remicade.
At week 24, all placebo-treated patients crossed over to infliximab induction. 
V 24. tednu so vsi s placebom zdravljeni bolniki prešli na uvajanje infliksimaba.
If these medicines do not work well enough, you will be given Remicade which you will take in combination with another medicine called methotrexate to: 
Če ta zdravila ne delujejo dovolj dobro, boste prejeli zdravilo Remicade skupaj z zdravilom, imenovanim metotreksat, za:
During Remicade treatment, other concomitant therapies, e.g., corticosteroids and immunosuppressants should be optimised. 
Med zdravljenjem z zdravilom Remicade je treba optimizirati druge sočasne terapije, npr. s kortikosteroidi in zdravili za zaviranje imunske odzivnosti.
• A type of blood cancer (lymphoma) 
• vrsta krvnega raka (limfom)
Due to its inhibition of TNF, infliximab administered during pregnancy could affect normal immune responses in the newborn. 
Ker infliksimab zavira TNF, lahko pri uporabi v času nosečnosti vpliva na normalni imunski odziv novorojenčka.
Powder for concentrate for solution for infusion 1 vial 100 mg 
prašek za koncentrat za raztopino za infundiranje 1 viala 100 mg
If a patient has an inadequate response or loses response after this period, consideration may be given to increase the dose step-wise by approximately 1.5 mg/kg, up to a maximum of 7.5 mg/kg every 8 weeks. 
Če se bolnik nezadostno odzove na zdravilo ali če pri njem odziv pozneje izgine, mu lahko tudi postopoma povečujete odmerek za približno 1,5 mg/kg na vsakih 8 tednov, do največ 7,5 mg/kg.
Use of TNF-blocking agents, including infliximab, has been associated with cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis, and peripheral demyelinating disorders, including Guillain-Barré syndrome. 
Uporaba zaviralcev TNF vključno z infliksimabom je bila povezana s primeri novega pojava oz. poslabšanja kliničnih simptomov in/ali z rentgenskimi znaki demielinizirajoče bolezni osrednjega živčevja, vključno z multiplo sklerozo, in demielinizirajoče bolezni perifernega živčevja, vključno z Guillain-Barréjevim sindromom.
In REACH, 17.5% of randomised patients experienced 1 or more infusion reactions. 
V preskušanju REACH se je pri 17,5 % naključno razvrščenih bolnikov pojavila ena oziroma več z infuzijo povezanih reakcij.
Population pharmacokinetic analysis based on data obtained from patients with ulcerative colitis (N = 60), Crohn's disease (N = 112), juvenile rheumatoid arthritis (N = 117) and Kawasaki disease (N = 16) with an overall age range from 2 months to 17 years indicated that exposure to infliximab was dependent on body weight in a non-linear way. 
Analiza populacijske farmakokinetike na podlagi podatkov, pridobljenih pri bolnikih z ulceroznim kolitisom (n = 60), Crohnovo boleznijo (N = 112), juvenilnim revmatoidnim artritisom (N = 117) in boleznijo Kawasaki (N = 16) v starostni skupini od 2 mesecev do 17 let, je pokazala, da je izpostavljenost infliksimabu nelinearno odvisna od telesne mase.
Cases of TB have been reported in patients treated with Remicade, even in patients who have already been treated with medicines for TB. 
Pri bolnikih, zdravljenih z zdravilom Remicade, so poročali o primerih tuberkuloze, tudi pri bolnikih, ki so že bili zdravljeni z zdravili proti TBC.